Donepezil in the treatment of progressive supranuclear palsy

G. Fabbrini, P. Barbanti, V. Bonifati, C. Colosimo, M. Gasparini, N. Vanacore, G. Meco

Research output: Contribution to journalArticlepeer-review


Objectives - To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods - Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results - Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions - Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder.

Original languageEnglish
Pages (from-to)123-125
Number of pages3
JournalActa Neurologica Scandinavica
Issue number2
Publication statusPublished - 2001


  • Donepezil
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Donepezil in the treatment of progressive supranuclear palsy'. Together they form a unique fingerprint.

Cite this